243 related articles for article (PubMed ID: 14745430)
1. Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.
Thornton PD; Gruszka-Westwood AM; Hamoudi RA; Atkinson S; Kaczmarek P; Morilla RM; Hilditch BL; A'Hern R; Matutes E; Catovsky D
Hematol J; 2004; 5(1):47-54. PubMed ID: 14745430
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
3. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
5. Relevance of TP53 for CLL diagnostics.
Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
[No Abstract] [Full Text] [Related]
6. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
7. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
[TBL] [Abstract][Full Text] [Related]
11. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
12. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
[TBL] [Abstract][Full Text] [Related]
13. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
[TBL] [Abstract][Full Text] [Related]
14. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.
Liu YC; Margolskee E; Allan JN; Mathew S; Bhavsar E; Casano J; Orazi A; Furman RR; Geyer JT
Mod Pathol; 2020 Mar; 33(3):344-353. PubMed ID: 31477813
[TBL] [Abstract][Full Text] [Related]
15. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia.
Ripollés L; Ortega M; Ortuño F; González A; Losada J; Ojanguren J; Soler JA; Bergua J; Coll MD; Caballín MR
Cancer Genet Cytogenet; 2006 Nov; 171(1):57-64. PubMed ID: 17074592
[TBL] [Abstract][Full Text] [Related]
16. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.
Fabris S; Mosca L; Todoerti K; Cutrona G; Lionetti M; Intini D; Matis S; Colombo M; Agnelli L; Gentile M; Spriano M; Callea V; Festini G; Molica S; Lambertenghi Deliliers G; Morabito F; Ferrarini M; Neri A
Genes Chromosomes Cancer; 2008 Sep; 47(9):781-93. PubMed ID: 18521849
[TBL] [Abstract][Full Text] [Related]
17. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
Lazarian G; Tausch E; Eclache V; Sebaa A; Bianchi V; Letestu R; Collon JF; Lefebvre V; Gardano L; Varin-Blank N; Soussi T; Stilgenbauer S; Cymbalista F; Baran-Marszak F
Int J Cancer; 2016 Oct; 139(8):1759-63. PubMed ID: 27270786
[TBL] [Abstract][Full Text] [Related]
19. Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.
Rudenko HC; Else M; Dearden C; Brito-Babapulle V; Jones C; Dexter T; Fenwick K; Mackay A; Ashworth A; Matutes E; Gonzalez D; Catovsky D; Morgan GJ
Leuk Lymphoma; 2008 Oct; 49(10):1879-86. PubMed ID: 18949611
[TBL] [Abstract][Full Text] [Related]
20. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]